These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12496994)

  • 1. What's hot in the prostate?
    Belldegrun A
    Prostate Cancer Prostatic Dis; 2002; 5(2):84-7. PubMed ID: 12496994
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 3. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and staging of prostate cancer.
    Flanigan RC
    J Urol; 1998 Aug; 160(2):443-4. PubMed ID: 9679894
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Scattoni V
    Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Joniau S
    Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
    Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
    BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer of the prostate. Diagnosis, prognosis, principles of treatment].
    Lopez JG; Perrin P
    Rev Prat; 1999 Feb; 49(3):297-301. PubMed ID: 10189800
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin-like growth factor I and prostate cancer.
    O'Brien MF; Watson RW; Fitzpatrick JM
    Urology; 2001 Jul; 58(1):1-7. PubMed ID: 11445469
    [No Abstract]   [Full Text] [Related]  

  • 10. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
    Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath K; Wessells H
    Ann Intern Med; 2012 Apr; 156(8):591-5. PubMed ID: 22351514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prostate cancer.
    Morton GC
    Curr Probl Cancer; 2000; 24(1):5-51. PubMed ID: 10749454
    [No Abstract]   [Full Text] [Related]  

  • 12. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
    Klotz L
    Curr Urol Rep; 2007 Sep; 8(5):341-4. PubMed ID: 17880830
    [No Abstract]   [Full Text] [Related]  

  • 14. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining the Clinical States of Prostate Cancer in the Modern Era.
    McKay R
    Oncology (Williston Park); 2021 Apr; 35(4):169. PubMed ID: 33877748
    [No Abstract]   [Full Text] [Related]  

  • 16. Predicting pathological stage of localized prostate cancer.
    Petros JA
    JAMA; 1997 Sep; 278(12):981; author reply 981-2. PubMed ID: 9307343
    [No Abstract]   [Full Text] [Related]  

  • 17. Racial differences in prostate carcinogenesis. Histologic and clinical observations.
    Fowler JE; Bigler SA
    Urol Clin North Am; 2002 Feb; 29(1):183-91. PubMed ID: 12109344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.
    Evans S; Metcalfe C; Patel B; Ibrahim F; Anson K; Chinegwundoh F; Corbishley C; Gillatt D; Kirby R; Muir G; Nargund V; Popert R; Wilson P; Persad R; Ben-Shlomo Y
    Br J Cancer; 2010 Jan; 102(2):249-54. PubMed ID: 19935788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials.
    Powell IJ; Meyskens FL
    Urology; 2001 Apr; 57(4 Suppl 1):178-81. PubMed ID: 11295621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine treatment: expected duration stage by stage.
    Schröder FH
    Prostate Suppl; 2000; 10():26-31. PubMed ID: 11056490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.